Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: another departure at Gilead, veteran researcher to head Karuna

Daily Brief: another departure at Gilead, veteran researcher to head Karuna

Targeting muscarinic receptors is one of the most promising approaches to treating both the psychosis and cognitive impairment that characterise many disabling neuropsychiatric disorders, including schizophrenia and Alzheimer’s disease, where

Latest news

More from news
Approximately 27 fully matching, plus 258 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

  • Pharma deals in February 2015 Pharma deals in February 2015

    in-house clinical and preclinical pipeline targeting serious diseases with blockbuster potential eg Alzheimer's disease, ADHD, metabolic disease, schizophrenia, migraine.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics